Hera Women's Health is highlighting results from the PRIME multicenter randomized controlled trial sponsored by Sera Prognostics, Inc., with Brian K. Iriye, MD (Hera Women's Health) serving as the ...

Investing.com -- Sera Prognostics Inc (NASDAQ:SERA) stock jumped 12% Wednesday after the company reported positive results from a large clinical trial of its PreTRM Test, which helps identify women at ...

The Company also hosted a virtual R&D day in conjunction with the SMFM Pregnancy Meeting further showcasing results of the PRIME study. During these events, Dr. Iriye shared a presentation ...

Sera Prognostics is a promising company with a mission to improve pregnancy outcomes through its blood test product, PreTRM, which identifies biomarkers linked to premature birth. Premature birth is a ...

The company reiterated plans to publish the PRIME study in a peer-reviewed journal by year-end and to host an investor and analyst event immediately following acceptance. Management expects a "steady ...

Sera Prognostics, which develops diagnostic tests for pregnancy complications, raised $75 million by offering 4.7 million shares at $16, within the range of $15 to $17. Sera Prognostics uses its ...

Sera Prognostics reported its Q3 2025 earnings, revealing a mixed financial performance. The company posted an earnings per share (EPS) of -$0.16, outperforming the forecasted -$0.23, marking a 30.43% ...

Established in 2018, the company leverages deep learning and machine learning algorithms to generate brain scan analyses to aid the assessment and early detection of neurological disorders, including ...